Compare CTW & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | CRDF |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4M | 130.7M |
| IPO Year | N/A | 2012 |
| Metric | CTW | CRDF |
|---|---|---|
| Price | $2.33 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 45.0K | ★ 730.0K |
| Earning Date | 05-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $1.10 | $1.48 |
| 52 Week High | $3.14 | $4.56 |
| Indicator | CTW | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 55.40 | 55.72 |
| Support Level | $1.88 | $1.51 |
| Resistance Level | $2.46 | $2.05 |
| Average True Range (ATR) | 0.26 | 0.08 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 62.75 | 84.48 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.